Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.

Yang LiuZhiling ZhangRuiqi LiuWensu WeiZitong ZhangLixin MaiShengjie GuoHui HanFangjian ZhouLiru HePei Dong

Published in: Radiation oncology (London, England) (2021)

Incorporating SBRT into anti-PD-1/TA therapy is safe and tolerable. Further investigation is needed, particularly in patients with clear-cell histology and a longer duration of response to first-line antiangiogenic therapy.

Keyphrases

metastatic renal cell carcinoma
radiation therapy
clear cell
early stage
radiation induced
locally advanced
bone marrow
rectal cancer